NASDAQ:CRMD CorMedix Q2 2025 Earnings Results & Report $7.38 +0.06 (+0.82%) Closing price 04:00 PM EasternExtended Trading$7.42 +0.04 (+0.50%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. CorMedix beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 7, 2025. The company reported EPS of $0.28 versus the $0.20 consensus estimate, while revenue of $39.74 million topped the $29.88 million estimate by $9.86 million. Revenue increased 4,830.1% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 7, 2025TimeBefore Market OpensConference Call7:30 AM ET CorMedix EPS ResultsActual EPS$0.28Consensus EPS $0.20Beat/MissBeat by +$0.08One Year Ago EPS-$0.25EPS Beat Rate7 of last 8 quartersCorMedix Revenue ResultsActual Revenue$39.74 millionExpected Revenue$29.88 millionBeat/MissBeat by +$9.86 millionYoY Revenue Growth+4,830.10%Upcoming EarningsCorMedix's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CorMedix Q2 2025 Earnings FAQ Did CorMedix beat earnings estimates for Q2 2025? CorMedix (NASDAQ:CRMD) reported earnings of $0.28 per share for Q2 2025, beating the consensus estimate of $0.20. The report was announced on Thursday, August 7, 2025. What was CorMedix's revenue for Q2 2025? CorMedix reported revenue of $39.74 million for Q2 2025, against a consensus estimate of $29.88 million. When is CorMedix's next earnings date? CorMedix's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for CorMedix on the company's earnings history page. CorMedix Earnings HeadlinesReviewing CorMedix (NASDAQ:CRMD) and Eyepoint Pharmaceuticals (NASDAQ:EYPT)October 4, 2026 | americanbankingnews.comCorMedix Inc (NASDAQ:CRMD) Stock Has Consensus Target Price of $15.00October 3, 2026 | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 9 at 1:00 AM | Stansberry Research (Ad)Oppenheimer initiates coverage of CorMedix at outperformSeptember 23, 2026 | msn.comOppenheimer avvia la copertura di CorMedix con rating outperformSeptember 23, 2026 | it.investing.comCorMedix出席富国银行第21届年度医疗健康大会：增长与风险并存September 10, 2026 | cn.investing.comSee More CorMedix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CorMedix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CorMedix and other key companies, straight to your email. Email Address About CorMedixCorMedix (NASDAQ:CRMD). is a biopharmaceutical company focused on developing and commercializing products designed to prevent and treat infectious and inflammatory diseases. The company’s lead product is DefenCath® (taurolidine and heparin), an antimicrobial catheter-lock solution intended to reduce the risk of catheter-related bloodstream infections in adult patients with kidney failure who receive chronic hemodialysis through a central venous catheter. The U.S. Food and Drug Administration approved DefenCath in 2023. The product is used to fill and lock the lumens of dialysis catheters between treatment sessions, helping protect against infection while maintaining catheter patency. CorMedix markets DefenCath in the United States and is focused on expanding its use within the U.S. dialysis-care market. CorMedix was founded in 2006 and is headquartered in Berkeley Heights, New Jersey. The company continues to evaluate additional applications for its taurolidine-based technology and related opportunities in infection prevention and other high-risk healthcare settings. David Mehalick serves as CorMedix’s president and chief executive officer.View CorMedix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
